Center for Biologics Evaluation and Research (CBER) has suspended the biologics license for Valneva’s Ixchiq (Chikungunya ...

In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a "danger to health".

The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.

A detail of a packaging of the Ixchiq chikungunya vaccine, in a pharmacy in Saint-Denis, La Réunion, is shown March 21. The ...

U.S. health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

HealthDay News — The US Food and Drug Administration (FDA) is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports ...

Mainland France has recorded an unprecedented rise in chikungunya cases this summer as the tiger mosquito spreads across the ...

Regeneron Pharmaceuticals’ shares closed up 2.7% to $587.65 as it announced that the primary and key secondary endpoints were ...